---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-325243"
form_type: "8-K"
ticker: "WHWK"
cik: "0001422142"
company_name: "Whitehawk Therapeutics, Inc."
filed_at: "2021-11-10T23:59:59+00:00"
generated_at: "2026-06-28T09:48:45.529211+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Aadi Q3 net loss $87.2M; FYARRO PDUFA Nov 26; cash $161.4M

## Summary
- FYARRO (nab-sirolimus) NDA under FDA priority review with PDUFA target Nov 26, 2021.
- Ended Q3 with $161.4M cash; expected runway into 2024 post merger & $155M PIPE.
- Net loss $87.2M for Q3, primarily from $74.2M non-cash impairment related to merger.
- Appointed Brendan Delaney COO, Loretta Itri CMO (Q4), Scott Giacobello CFO (Nov 28).
- Plan to initiate registrational trial in TSC1/TSC2 tumors by end 2021 or early 2022.

## SEC filing metadata
- accession: 0001193125-21-325243
- form_type: 8-K
- ticker: WHWK
- cik: 0001422142
- company_name: Whitehawk Therapeutics, Inc.
- filed_at: 2021-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1422142/000119312521325243/0001193125-21-325243-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1422142/000119312521325243/d249085d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-325243
- JSON: https://secwatch.observer/filing/0001193125-21-325243.json
- Plain text: https://secwatch.observer/filing/0001193125-21-325243.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.